ASLN Oct 2024 2.500 call
| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0500 |
| Ask | 0.1500 |
| Strike | 2.50 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.0500 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 600 |
GlobeNewswireASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares (“ADSs”) to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing tw
ZacksAll You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy
ASLAN Pharmaceuticals (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksHere's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher
ASLAN Pharmaceuticals (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
